Heterogeneous glycosylation patterns of human PAI-1 may reveal its cellular origin.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Thrombosis Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.thromres.2008.04.008PMID 18508114
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasminogen activator inhibitor 1 expression in platelets is not influenced by the 4G/5G promoter polymorphism.

  2008cited by this paper
• Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis.

  2007cited by this paper
• Glycoproteomics based on tandem mass spectrometry of glycopeptides.

  2007cited by this paper
• Plasminogen activator inhibitor-1, adipose tissue and insulin resistance

  2007cited by this paper
• Human visceral adipose tissue and the plasminogen activator inhibitor type 1

  2007cited by this paper
• Mass spectrometric analysis of N- and O-glycosylation of tissues and cells.

  2006cited by this paper
• Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease

  2005cited by this paper
• Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise.

  2005cited by this paper
• Regulation of local availability of active tissue‐type plasminogen activator in vivo in man

  2004cited by this paper
• Platelets synthesize large amounts of active plasminogen activator inhibitor 1.

  2004cited by this paper
• Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk

  2004cited by this paper
• Structural analysis of 2D-gel-separated glycoproteins from human cerebrospinal fluid by tandem high-resolution mass spectrometry.

  2003cited by this paper
• Biochemical importance of glycosylation of plasminogen activator inhibitor-1

  2003cited by this paper
• Acute Release of Plasminogen Activator Inhibitor-1 in ST-Segment Elevation Myocardial Infarction Predicts Mortality

  2003cited by this paper
• Stromal Cells Are the Main Plasminogen Activator Inhibitor‐1‐Producing Cells in Human Fat: Evidence of Differences Between Visceral and Subcutaneous Deposits

  2002cited by this paper
• Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss

  2001cited by this paper
• Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction.

  2000cited by this paper
• The Plasma Levels of Prostanoids and Plasminogen Activator Inhibitor-1 in Primary and Secondary Thrombocytosis

  2000cited by this paper
• Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity.

  2000cited by this paper
• Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo.

  1999cited by this paper
• PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level.

  1999cited by this paper
• Essentials of Glycobiology

  1999cited by this paper
• Impaired capacity for endogenous fibrinolysis in essential hypertension

  1998cited by this paper
• Impaired capacity for endogenous fibrinolysis in essential hypertension.

  1998cited by this paper
• Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.

  1998cited by this paper
• The adipocyte and hemostatic balance in obesity: studies of PAI-1.

  1998cited by this paper
• Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels.

  1997cited by this paper
• Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha.

  1997cited by this paper
• Peptide Sequencing by Mass Spectrometry for Homology Searches and Cloning of Genes

  1997cited by this paper
• Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene.

  1997cited by this paper
• High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.

  1994cited by this paper
• The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue.

  1994cited by this paper
• Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator.

  1994cited by this paper
• Separation of active and inactive forms of recombinant human plasminogen activator inhibitor type 1 (PAI-1) expressed in Chinese hamster ovary cells: comparison with native human PAI-1.

  1994cited by this paper
• Atheromatous plaque macrophages produce plasminogen activator inhibitor type-1 and stimulate its production by endothelial cells and vascular smooth muscle cells.

  1993cited by this paper
• Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes.

  1993cited by this paper
• Reduction in Factor VII, Fibrinogen and Plasminogen Activator Inhibitor-1 Activity after Surgical Treatment of Morbid Obesity

  1992cited by this paper
• Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.

  1991cited by this paper
• Distribution of plasminogen activator inhibitor (PAI-1) in tissues.

  1991cited by this paper
• A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.

  1991cited by this paper
• The platelet and plasma pools of plasminogen activator inhibitor (PAI‐1) vary independently in disease

  1990cited by this paper
• Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo.

  1990cited by this paper
• The majority of type 1 plasminogen activator inhibitor associated with cultured human endothelial cells is located under the cells and is accessible to solution-phase tissue-type plasminogen activator

  1990cited by this paper
• Plasminogen Activator Inhibitor 1 and Plasminogen Activator Inhibitor 2 in Various Disease States

  1988cited by this paper
• Plasminogen activator inhibitor (PAI‐1) in plasma and platelets

  1988cited by this paper
• Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

  1987cited by this paper
• The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma.

  1985cited by this paper
• The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related.

  1985cited by this paper
• Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.

  1985cited by this paper
• Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

  1973cited by this paper

• Tissue plasminogen activator modified thromboelastography identifies fibrinolysis resistance in dogs with immune-mediated hemolytic anemia

  2025cites this paper
• Dogs with sepsis are more hypercoagulable and have higher fibrinolysis inhibitor activities than dogs with non-septic systemic inflammation

  2025cites this paper
• Potential Biomarkers for Early Diagnosis, Evaluation, and Prognosis of Sepsis-Induced Coagulopathy

  2023cites this paper
• “Super” SERPINs—A stabilizing force against fibrinolysis in thromboinflammatory conditions

  2023cites this paper
• Platelet protein synthesis, regulation, and post-translational modifications: mechanics and function

  2023cites this paper
• Identification of Genomic Loci Regulating Platelet Plasminogen Activator Inhibitor-1 in Mice.

  2023cites this paper
• Human Angiotensin I-Converting Enzyme Produced by Different Cells: Classification of the SERS Spectra with Linear Discriminant Analysis

  2022cites this paper
• Elevated plasma levels of plasminogen activator inhibitor‐1 are associated with risk of future incident venous thromboembolism

  2022cites this paper
• The role of the platelet pool of Plasminogen Activator Inhibitor-1 in well-controlled type 2 diabetes patients

  2022cites this paper
• Role of Plasminogen Activation System in Platelet Pathophysiology: Emerging Concepts for Translational Applications

  2022cites this paper
• Identification of soluble thrombomodulin and tissue plasminogen activator-inhibitor complex as biomarkers for prognosis and early evaluation of septic shock and sepsis-induced disseminated intravascular coagulation.

  2021cites this paper
• Plasminogen activator inhibitor‐1: a potential etiological role in livedoid vasculopathy

  2020cites this paper
• Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition

  2020cites this paper
• Performance of plasminogen activator inhibitor-1 as a biomarker in patients undergoing coronary angiography: Analytical and biological considerations

  2019cites this paper
• Conformational fingerprint of blood and tissue ACEs: Personalized approach

  2018cites this paper
• Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis

  2017cites this paper
• ACE phenotyping in human heart

  2017cites this paper
• Differential response of plasma plasminogen activator inhibitor 1 after weight loss surgery in patients with or without type 2 diabetes.

  2017cites this paper
• Development of a plasminogen activator inhibitor (PAI-1) assay and comparison of plasma PAI-1 activity in hyperlipidemic/dyslipidemic dogs with either hyperadrenocorticism or diabetes mellitus, and healthy dogs.

  2017cites this paper
• Liquid chromatography-tandem mass spectrometry-based fragmentation analysis of glycopeptides

  2016cites this paper
• LINE-1 and inflammatory gene methylation levels are early biomarkers of metabolic changes: association with adiposity

  2016cites this paper
• Pharmacological stimulation of endothelial function and long-term impact of hypertension in man

  2016influential citation
• Epigenetic influence on cardiovascular protective mechanisms in vivo: explorations of t-PA release and extracellular vesicle genetic content

  2015cites this paper
• Tissue Specificity of Human Angiotensin I-Converting Enzyme

  2015cites this paper
• Psoriasis and Metabolic Syndrome

  2015cites this paper
• Functional Stability of Plasminogen Activator Inhibitor-1

  2014cites this paper
• Profibrinolytic Effect of the Epigenetic Modifier Valproic Acid in Man

  2014cites this paper
• [The synthesis of proteins in unnucleated blood platelets].

  2013cites this paper
• Plasminogen Activator Inhibitor-1 and Thrombotic Cerebrovascular Diseases

  2012cites this paper
• The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo.

  2012cites this paper
• Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1.

  2012cites this paper
• Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo.

  2011cites this paper
• Energy‐Restricted High‐Fat Diets Only Partially Improve Markers of Systemic and Adipose Tissue Inflammation

  2011cites this paper
• Mass spectrometry of peptides and proteins from human blood.

  2011cites this paper
• Genetic and nutritional studies to elucidate the role of adipose tissue in the pathogenesis of metabolic syndrome

  2011cites this paper
• Basic Science Advances for Clinicians

  2011cites this paper
• Metabolic Factors, Adipose Tissue, and Plasminogen Activator Inhibitor-1 Levels in Type 2 Diabetes: Findings From the Look AHEAD Study

  2011cites this paper
• Metabolic Factors , Adipose Tissue , and Plasminogen Activator Inhibitor-1 Levels in Type 2 Diabetes Findings From the Look AHEAD Study

  2011cites this paper
• Plasminogen Activator Inhibitor-1 Regulates Myoendothelial Junction Formation

  2010cites this paper
• Structural and functional peculiarities of plasminogen activator inhibitor PAI-1

  2010cites this paper
• On the Regulation of the Serine Protease t-PA and its Inhibitor PAI-1 in the Brain

  2010cites this paper
• Visceral Adiposity, Insulin Resistance, and Type 2 Diabetes

  2010cites this paper
• Tissue‐type plasminogen activator‐plasmin‐BDNF modulate glutamate‐induced phase‐shifts of the mouse suprachiasmatic circadian clock in vitro

  2009cites this paper
• Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats.

  2009cites this paper
• Protein synthesis by platelets: historical and new perspectives

  2009cites this paper
• The multiplex bead array approach to identifying serum biomarkers associated with breast cancer

  2009cites this paper
• Development of a New Biomechanical ex vivo Perfusion System - Studies on effects of biomechanical and inflammatory stress on hemostatic genes in human vascular endothelium

  2009cites this paper
• Mechanisms and effects of low plasminogen activator inhibitor type 1 activity

  2008cites this paper